Sun Pharma Share Price Target 2026: Analyst Consensus, Bull Case & Bear Case

Mon Apr 13 2026

Sun Pharma (Pharmaceuticals / Specialty) is trading at Rs 1,580 as of April 2026, with a 52-week range from Rs 1,480 to Rs 2,000 and a 1-year return of -20%. The analyst consensus 12-month Sun Pharma share price target stands at Rs 1,900-2,100 — implying meaningful potential movement from current levels.

Whether you are a long-term holder reassessing your position or a new investor evaluating entry levels, understanding where analysts see Sun Pharma heading over the next 12-24 months requires looking beyond the CMP. This article covers the key catalysts and risks, technical levels, institutional positioning, and a structured breakdown of the short-term, 12-month, and long-term Sun Pharma share price targets.

Click Here — Get Free Investment Predictions on Univest.

Table of Contents

Sun Pharma Key Data — CMP, Valuation, Fundamentals

Parameter	Value
CMP (April 2026)	Rs 1,580
52-Week High	Rs 2,000
52-Week Low	Rs 1,480
1-Year Return	-20%
Trailing P/E	38x
Price-to-Book	6.8x
Market Cap	Rs 3.8L Cr
Sector	Pharmaceuticals / Specialty
Promoter Holding	54.5%
FII Holding	21.8%
DII Holding	16.4%

Track live Sun Pharma fundamentals and analyst ratings on the Univest Screener.

Sun Pharma Share Price Targets — Short-Term, 12-Month & Long-Term

Access premium analyst research on Univest.

Scenario	Target	Basis
Short-Term (3-6M)	Rs 1,900	Technical support; near-term catalyst
12-Month Consensus	Rs 1,900-2,100	Analyst consensus based on current fundamentals
Bull Case (FY28)	Rs 2,500	Full execution of growth catalysts below
Bear Case	Rs 1,300	Materialisation of key risks below

Bull Case — What Has to Go Right for Sun Pharma

1. US specialty franchise (Ilumya, Cequa, Odomzo) generating $1.2+ billion and growing at 15% CC annually

US specialty franchise (Ilumya, Cequa, Odomzo) generating $1.2+ billion and growing at 15% CC annually

2. India branded generics market leadership (10%+ market share in key therapy areas)

India branded generics market leadership (10%+ market share in key therapy areas)

3. GLP-1 (Semaglutide-class) obesity drug GL0034 in Phase 2

potentially transformational if Phase 3 data positive

4. Organon acquisition optionality

if executed successfully, doubles US commercial scale

5. Emerging market specialty expansion in dermatology and ophthalmology across 45+ countries

Emerging market specialty expansion in dermatology and ophthalmology across 45+ countries

Bear Case — Key Risks to the Sun Pharma Share Price Target

Risk 1: Ilumya biosimilar entry in FY27-28 materially reducing the highest-margin US product revenue

Ilumya biosimilar entry in FY27-28 materially reducing the highest-margin US product revenue

Risk 2: Organon acquisition completing with adverse terms, creating leveraged balance sheet without commensurate earnings accretion

Organon acquisition completing with adverse terms, creating leveraged balance sheet without commensurate earnings accretion

Risk 3: US 26% pharma tariff expansion beyond APIs to finished formulations

US 26% pharma tariff expansion beyond APIs to finished formulations

Institutional Sentiment and Technical Analysis

Sun Pharma has 21.8% FII holding and 16.4% DII holding. High FII ownership of 21.8% means the stock is sensitive to global risk-off events — FII selling can be disproportionate to any specific negative news.

Technically, Sun Pharma is trading at Rs 1,580 against a 52-week range of Rs 1,480 to Rs 2,000. The -20% 1-year return positions the stock in negative territory — creating both risk of further downside and opportunity for mean reversion. The 12-month analyst target of Rs 1,900-2,100 implies the stock is expected to recover meaningfully from current depressed levels.

Download the Univest iOS App or Univest Android App for real-time research and analyst updates.

Conclusion — Our View on ${name} Share Price Target

Sun Pharma at Rs 1,580 is at its most attractive entry point in 18 months. The specialty US business ($1.2 billion and growing), India market leadership, and emerging market expansion provide a diversified growth platform. The Organon deal uncertainty is a risk, not a certainty. At 38x P/E on FY26 earnings, the stock offers value if US specialty continues growing at 15%. 12-month target of Rs 1,900-2,100 implies 20-33% upside.

Subscribe to Univest Pro for SEBI-registered analyst recommendations — entry, target, stop-loss.

Frequently Asked Questions

Q1. What is Sun Pharma share price target 2026?

Sun Pharma share price target for 2026 is Rs 1,900-2,100 based on analyst consensus. The bull case target is Rs 2,500 and the bear case is Rs 1,300. These are analyst estimates, not guaranteed returns.

Q2. Is Sun Pharma a good buy now?

Sun Pharma is trading at Rs 1,580 against a 52-week range of Rs 1,480 to Rs 2,000. Analyst consensus target of Rs 1,900-2,100 implies upside from current levels. Consult a SEBI-registered financial advisor before investing.

Q3. What is Sun Pharma’s current valuation?

Sun Pharma trades at a trailing P/E of 38x and price-to-book of 6.8x with a market capitalisation of Rs 3.8L Cr. The stock’s valuation relative to earnings growth determines the appropriate entry point.

Q4. What are the key risks for Sun Pharma?

Key risks for Sun Pharma include the factors outlined in the Bear Case section of this article. Ilumya biosimilar entry in FY27-28 materially reducing the highest-margin US product revenue is the primary near-term risk to watch.

Q5. Where can I track Sun Pharma share price live?

Track Sun Pharma share price live, quarterly results, FII/DII activity, and analyst ratings on the Univest Screener at univest.in/screeners. Download the Univest iOS or Android App for daily research.

Disclaimer: Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. All analyst targets are estimates and may change. Verify all numbers before investing. Consult a SEBI-registered financial advisor before making any investment decisions.For more stock research, visit Univest Blogs.